


Trial description: Patients with symptomatic HF and 3-4+ MR on maximally tolerated guideline-directed medical therapy (GDMT) were randomized to MitraClip (MC) + GDMT vs. GDMT alone. Patients were followed for 24 months.



RESULTS

- Primary effectiveness endpoint, HF hospitalization: MC + GDMT vs. GDMT: 35.8% vs. 67.9%, HR 0.53, 95% CI 0.40-0.70, p < 0.001
- Primary safety endpoint: freedom from device-related complications at 12 months: 96.6% for MC, p < 0.001
- All-cause mortality: 29.1% vs. 46.1%, p < 0.001

CONCLUSIONS

- Landmark trial; transcatheter mitral valve repair with MC on a background of maximally tolerated GDMT was superior to GDMT alone in reducing HF hospitalization and mortality in symptomatic HF patients with 3-4+ MR

Stone GW, et al. N Engl J Med 2018;Sep 23:[Epub]